TUBA1C and prostate adenocarcinoma: We found that TUBA1C showed higher expression in tumour samples in BLCA, BRCA, CESC, bile duct cancer (CHOL), COAD, oesophageal cancer (ESCA), GBM, HNSC, kidney chromophobe (KICH), kidney clear cell carcinoma (KIRC), kidney papillary cell carcinoma (KIRP), LIHC, LUAD, LUSC, prostate cancer (PRAD), READ, STAD and UCEC.